ADIL
Adial Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$2.50M
P/E Ratio
—
EPS
$-11.93
Beta
1.40
52W High
$21.38
52W Low
$1.54
50-Day MA
$2.76
200-Day MA
$7.10
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Adial Pharmaceuticals Inc
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies for the treatment or prevention of addictions and related disorders. The company is headquartered in Charlottesville, Virginia.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-7.80M |
| Operating Margin | 0.00% |
| Return on Equity | -170.70% |
| Return on Assets | -83.20% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $4.75 |
| Price-to-Book | 0.46 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -0.49 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $1.43M |
| Float | $1.31M |
| % Insiders | 1.62% |
| % Institutions | 9.91% |
Analyst Ratings
Consensus ($23.33 target)
1
Strong Buy2
BuyData last updated: 4/7/2026